There are currently no generic versions of Apidra (insulin glulisine) available. Apidra is considered a "biologic" medication, and is regulated under different laws than most other medications. At this time, generic Apidra (or any other generic biologic) is prohibited from being manufactured in the United States. Also, a patent prevents any generic form of Apidra from being made until at least June 2018, when the patent expires.
Generic Apidra: An OverviewApidra® (insulin glulisine) is a prescription diabetes medication. It is a rapid-acting form of insulin approved to treat both type 1 and type 2 diabetes.
Apidra is made by sanofi-aventis. At this time, no generic versions of Apidra are available.
When Will Generic Apidra Be Available?This is a difficult question to answer. There are at least two major obstacles preventing generic Apidra from becoming available. First, Apidra is considered a "biologic" medication and is, therefore, under different rules and laws than most other medications. At this point, generic biologics, including generic Apidra, are not allowed to be manufactured in the United States. Currently, legislation is under way that may change the laws concerning generic biologics, but it is not clear when (or even if) this may happen.
Second, Apidra is protected by at least one unexpired patent, which is currently set to expire in June 2018. Even if the laws change and allow generic versions of insulins, generic Apidra would not be expected to become available until 2018.
Is Insulin Glulisine the Same as Generic Apidra?No -- insulin glulisine is the active ingredient in Apidra, but is not a generic version of it. What can be confusing is that, oftentimes, the active ingredient of a drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.